Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is pleased to announce that it has received a Certificate of Grant and recordal of patent under section 43 of the Patents Act in respect of patent application no. 202117034253 with the Government of India, originally applied for by Intramont Technologies, Inc. ("Intramont").
The duration of the patent granted in India is twenty (20) years from the effective filing date of the application, or until March 16, 2040.
Posted In: MGRX